Dr. Crawley has been with the Chronic Diseases Program at the Ottawa Hospital Research Institute since April 2012. In addition to being a Scientist with the OHRI, she is also an Assistant Professor at the University of Ottawa and Carleton University, where she teaches immunology at the undergraduate, graduate and medical school levels. She teaches these courses in both English and French. Dr. Crawley has earned 2 salary awards: a CIHR New Investigator Award and an Ontario HIV Treatment Network (OHTN) Junior Investigator Development Award. Her research is funded by the OHTN, Canadian Foundation of AIDS Research,, the J.P. Bickell Medical Research Foundation and the Natural Sciences and Engineering Research Council.
Dr. Crawley received a B.Sc. in Microbiology and Immunology from McGill University in Montreal, Quebec (Canada) in 1999. In 2004 she completed a Ph.D. in Immunology with Dr. Bruce N. Wilkie in the Dept. of Pathobiology at the University of Guelph’s Ontario Veterinary College (Guelph, Ontario, Canada). Dr. Crawley then trained as a postdoctoral fellow in Dr. Jonathan B. Angel’s laboratory at the Ottawa Hospital Research Institute, and published 10 peer-reviewed scientific research and review articles on the immunopathogenesis of HIV infection. Dr. Crawley was funded by an Ontario HIV Treatment Network (OHTN) Fellowship award and awarded a University of Ottawa Faculty of Medicine Postdoctoral Award of Excellence (2007).
Industry Expertise (2)
Areas of Expertise (12)
Hepatitis C Virus Infection (Hcv)
Hepatocellular Carcinoma (HCC)
New Investigator Award (professional)
Canadian Institutes of Health Research
Salary award (2013-2018)
Research Funding (2011-present) (professional)
- Natural Sciences and Engineering Research Council
- Ontario HIV Treatment Network
- Canadian Foundation of AIDS Research
- J.P. Bickell Foundation
- Canadian Hepatitis C Network (student scholarships)
Junior Investigator Development Award (professional)
Ontario HIV Treatment Network
Salary award and Research funding (2011-2015)
Postdoctoral Fellowship (professional)
Ontario HIV Treatment Network
Salary award (2007-2010)
Postdoctoral Award of Excellence (professional)
University of Ottawa Faculty of Medicine
University of Guelph: Ph.D., Immunology 2004
McGill University: B.S., Microbiology and Immunology 1999
- Assistant Professor University of Ottawa Dept. Biochem. Microbiol. Immunol.
- Adjunct Professor Carleton University Dept. Biol.
Media Appearances (1)
Ottawa student wins national science contest
One lab after another turned him down until Angela Crawley of the Ottawa Hospital Research Institute took him in. She does HIV work ...
Generalized CD8+ T-cell impairment in chronic hepatitis C virus (HCV) infection and the contribution of liver-infiltrating CD8+ T-cells to the immunopathogenesis of this infection remain poorly understood. It is hypothesized that this impairment is partially due to reduced CD8+ T-cell activity in response to cytokines such as IL-7, particularly within the liver. To investigate this, the phenotype and cytokine responsiveness of blood- and liver-derived CD8+ T-cells from healthy controls and individuals with HCV infection were compared.
The influence of sex on hepatitis C virus (HCV)-related outcomes is often neglected. The effects of sex on liver fibrosis progression and the effect of socioeconomic status on management are unclear.
Many soluble cytokine receptors inhibit cytokine bioactivity, while others prolong ligand activity. The biological role of an endogenous soluble form of IL-7Rα, or its therapeutic effects on CD8+ T-cells are unknown. We demonstrate that recombinant IL-7Rα-Fc, when pre-incubated with IL-7, enhances IL-7-induced CD8+ T-cell proliferation and viability of human or murine CD8+ T-cells.
IL-7 plays an important role in T cell survival, function, and memory cell development, yet the role of cytokine signaling pathways in these processes has not been fully elucidated. Moreover, the underlying mechanisms for the observed impairment of IL-7 activity in diseases, such as HIV infection, breast cancer, and autoimmunity, are not well understood.
Interleukin-7 (IL-7) is critical for early T-cell development and plays an important role in T-cell homeostasis, differentiation and function. Signalling via the IL-7 receptor is dependent on the expression of its components, IL-7Rα (CD127) and IL-2Rγ (CD132) and is mediated in part by alterations in CD127 expression levels in different cell subsets.